Jim Simons Rubius Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.14 - $0.31 $10,024 - $22,196	71,600 Added 55.68%	200,190 $35,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $321,019 - $900,249	-697,868 Reduced 84.44%	128,590 $56,000
Q2 2022 Aug 12, 2022	BUY	$0.79 - $5.98 $561,840 - $4.25 Million	711,190 Added 616.99%	826,458 $703,000
Q1 2022 May 13, 2022	BUY	$4.25 - $10.4 $188,334 - $460,865	44,314 Added 62.45%	115,268 $635,000
Q4 2021 Feb 11, 2022	BUY	$9.68 - $17.74 $488,394 - $895,053	50,454 Added 246.12%	70,954 $687,000
Q3 2021 Nov 12, 2021	BUY	$17.6 - $25.91 $360,800 - $531,155	20,500 New	20,500 $367,000
Q2 2021 Aug 13, 2021	SELL	$22.26 - $28.43 $1.4 Million - $1.79 Million	-63,000 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$8.02 - $32.01 $1.03 Million - $4.1 Million	-127,989 Reduced 67.01%	63,000 $1.67 Million
Q4 2020 Feb 10, 2021	SELL	$4.23 - $8.73 $311,915 - $643,741	-73,739 Reduced 27.85%	190,989 $1.45 Million
Q3 2020 Nov 13, 2020	BUY	$4.65 - $6.25 $507,910 - $682,675	109,228 Added 70.24%	264,728 $1.33 Million
Q2 2020 Aug 13, 2020	BUY	$4.01 - $6.88 $623,555 - $1.07 Million	155,500 New	155,500 $930,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.